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Gamma delta T lymphocytes (gdT cells) have pleiotropic properties including innate cytotoxicity, which make them
attractive effectors for cancer immunotherapy. Combination treatment with zoledronic acid and IL-2 can activate and
expand the most common subset of blood gdT, which express the Vg9Vd2 T cell receptor (TCR) (Vd2 T cells). Vg9Vd2 T
cells are equipped for antibody-dependent cell-mediated cytotoxicity (ADCC) through expression of the low-afﬁnity
FcgR CD16. GD2 is a highly ranked tumor associated antigen for immunotherapy due to bright expression on the cell
surface, absent expression on normal tissues and availability of therapeutic antibodies with known efﬁcacy in
neuroblastoma. To explore the hypothesis that zoledronic acid, IL-2 and anti-GD2 antibodies will synergize in a
therapeutic combination, we evaluated in vitro cytotoxicity and tumor growth inhibition in the GD2 expressing cancers
neuroblastoma and Ewing’s sarcoma. Vd2 T cells exert ADCC against GD2-expressing Ewing’s sarcoma and
neuroblastoma cell lines, an effect which correlates with the brightness of GD2 expression. In an immunodeﬁcient
mouse model of small established GD2-expressing Ewing’s sarcoma or neuroblastoma tumors, the combination of
adoptively transferred Vd2C T cells, expanded in vitro with zoledronic acid and IL-2, with anti-GD2 antibody ch14.18/
CHO, and with systemic zoledronic acid, signiﬁcantly suppressed tumor growth compared to antibody or gdT cell-free
controls. Combination treatment using ch14.18/CHO, zoledronic acid and IL-2 is more effective than their use in
isolation. The already-established safety proﬁles of these agents make testing of the combination in GD2 positive
cancers such as neuroblastoma or Ewing’s sarcoma both rational and feasible.
Introduction
gdT cells are T cells that share characteristics of the innate
immune system, recognizing markers of cellular stress or altered-
self in an MHC-independent manner.1,2 This makes them
potentially potent mediators of antitumor immunotherapy.
However, they comprise only a small percentage of circulating T
cells, and many tumors have developed means of evading gdT
cell-mediated killing. There are a number of subsets of gdT cells,
defined by their Vg and Vd chain usage, of which the most com-
mon in human blood expresses a relatively invariant Vg9Vd2
TCR. Vg9Vd2C gdT cells have previously been shown to be
potent killers of a range of hematological and solid tumor cell
lines3-5 but in the majority of cases their cytotoxicity is signifi-
cantly enhanced by target opsonization; and in diseases such as
neuroblastoma is almost entirely antibody dependent,5,6 which is
in part a reflection of that cancer’s immunoinhibitory environ-
ment. For example, neuroblastoma cells secrete immunosuppres-
sive factors such as soluble ligands of NKG2D, down regulate
HLA-class I and produce immunosuppressive cytokines.7–9 It is
unknown whether neuroblastoma cells are deficient in produc-
tion of Vg9Vd2 gdTCR ligands such as phosphoantigens. From
a cellular therapy perspective however, Vg9Vd2C gdT cells are
the most immediately feasible subset on account of the relative
ease of expanding their numbers in vivo using the combination
of zoledronate and IL-2, about which there is pre-existing safety
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data.6 There is some evidence of clinical efficacy in hematological
and solid malignancy10 but results have been variable suggesting
that additional combination treatments are required fully to har-
ness the antitumor potential of gdT cells.
Neuroblastoma strongly expresses GD2, a ganglioside anti-
gen, which is only very sparsely expressed on healthy tissue.
Gangliosides are molecules composed of glycosphingolipids asso-
ciated with one or more sialic acid residues. A number of mono-
clonal antibodies targeting GD2 are already in clinical use with
promising results,11–13 although the mechanism underlying their
action has not been fully elucidated. Immunotherapy using
GD2-targeting antibodies has become a component of standard
of care, first line treatment for high risk neuroblastoma, identify-
ing this cancer type as an attractive model for development of
further GD2-targeting immunotherapies. GD2 has been found
at varying levels of expression on a number of other tumor types
including Ewing’s sarcoma,14 small cell lung cancer,15 osteosar-
coma16 and melanoma17 suggesting that GD2-targeted immuno-
therapy should be further explored outside the neuroblastoma
field. Indeed, its favorable differential expression has led to GD2
being ranked 12th in the National Cancer Institute list of most
promising cancer antigens.18
Many immunotherapies that have been evaluated in clinical
trials involve combinations of modalities. For example, in neuro-
blastoma the combination of cytokines (IL-2C/– GM-CSF) with
anti-GD2 monoclonal antibodies has been evaluated clini-
cally.11–13 Researchers exploiting gdT cell-based immunotherapy
have adopted two broad strategies; either stimulating a patient’s
gdT cells in vivo using systemic administration of zoledronate
and IL-2, or using these agents for ex vivo expansion and adoptive
transfer. Given the evidence that the cytotoxicity of Vg9Vd2C
gdT cells is significantly enhanced by target opsonization, there
is a rationale for determining the efficacy of therapeutic combina-
tions of lytic antibodies with agents to activate and expand gdT
cells.19 Ch14.18 is a therapeutic anti-GD2 antibody currently in
evaluation in a number of clinical trials, and thought to function
predominantly by ADCC. It has not been extensively evaluated
for killing function in combination with zoledronate and IL-2 in
a range of cancer types expressing GD2. Here, we demonstrate
that the combination of Vg9Vd2C gdT cells, zoledronate and
ch14.18 produced in CHO cells (ch14.18/CHO) leads to signifi-
cant reductions in tumor growth compared to gdT cells and
zoledronate alone, in two GD2-expressing disease models.
Results
Vd1C and Vd1–/Vd2– gdT cells kill Ewing’s sarcoma cell
lines in an antibody-independent manner
Ewing’s sarcoma has been reported as expressing GD2, mak-
ing it a possible target for GD2-directed immunotherapy. We
first evaluated the cytotoxic properties, against Ewing’s cells, of
gdT cells expanded using anti-gdTCR coated artificial antigen
presenting cells as we have previously described.5 Vd1C (Fig. 1A)
and Vd1¡/Vd2¡ (Fig. 1B) gdT cells killed a range of Ewing’s
sarcoma cell lines with varying levels of potency (range of killing
of lines at 10:1 ET ratio of 15% to 55%, figures represent one of
five representative donors). The addition of GD2-opsonizing
antibody ch14.18/CHO made no significant difference to the
level of cytotoxicity against any of the Ewing’s sarcoma cell lines
tested. This is consistent with our previous findings against neu-
roblastoma5 which indicate that Vd1C and Vd1–/Vd2– gdT cell
cytotoxicity is antibody independent.
GD2 on Ewing’s sarcoma is an attractive target
for Vg9Vd2C gdT cell-mediated ADCC
There is currently no established method for specifically
expanding Vd1C or Vd1–/Vd2– gdT cells in vivo, whereas
Vg9Vd2C gdT cell numbers can be increased both in blood and
ex vivo using the combination of zoledronate and IL-2. Addition
of zoledronate to target cells can also increase expression of
Vg9Vd2C TCR ligands, and thereby potentially sensitize them
to Vg9Vd2 TCR-dependent killing. We first evaluated the effect
of addition of 5 mM zoledronate to the Ewing’s sarcoma line
TC71, and observed a marked increase in sensitivity to killing by
zoledronate-expanded Vg9Vd2C gdT cells, only after a pro-
longed 24 h exposure (Fig. 2A, n D 7). However, after a stan-
dard intravenous dose, zoledronate has a peak plasma
concentration of 1.13 mM, falling to <1% of this within 24 h20
suggesting the in vitro effect might not be translatable into clini-
cal relevance. We therefore investigated whether combination
treatment with antibody might be a more clinically relevant use
of zoledronate-activated gdT cells to kill Ewing’s sarcoma. GD2
was found to be heterogeneous for expression on Ewing’s cell
lines as judged by surface staining and flow cytometric analysis.
While lower than that seen in the established GD2bright neuro-
blastoma lines Kelly and LAN1 (Fig. 2B and Fig. S1), 9/10
Ewing’s sarcoma lines had detectable expression of GD2 com-
pared with isotype control staining. This is in agreement with
other published data14,21 regarding GD2 expression in Ewing’s
sarcoma, and indicates that the antibody-dependent killing
potential of Vd2C gdT cells could be exploited in this context.
We generated isogenic GD2bright clones of the naturally GD2dim
Ewing’s sarcoma cell line DC-ES6 to allow us to determine anti-
gen specific effects without confounding factors such as varying
expression of other gdT cell stimulating ligands. GD2 expression
in these engineered DC-ES6-GD2 cells was almost as bright as
that seen on neuroblastoma lines LAN1 and Kelly (Fig. 2B).
Vd2C gdT cells exhibit cytotoxicity against Ewing’s sarcoma
cell lines
We next evaluated ch14.18/CHO antibody-dependent and
-independent killing of Ewing’s lines by Vd2C gdT cells
expanded using zoledronate or isopentenyl-5-pyrophosphate C
IL-2. The antibody-independent killing in a 4 h cytotoxicity
assay was in the range of 10–20% at E:T ratio of 10:1 (Fig. 3A,
n D 3–6). Augmentation of cytotoxicity by target opsonization
with ch14.18 was only observed in the GD2bright cell line TC71
(p D 0.006, n D 6). Some enhancement of cytotoxicity was seen
against Ewing’s sarcoma cell lines expressing lower amounts of
GD2 but this was not significant. Hence, there appeared to be a
threshold level of GD2 below which ADCC was not observed.
e1025194-2 Volume 5 Issue 1OncoImmunology
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To confirm that this observation was due to the level of GD2
expression rather than other differences between cell lines, we
compared killing of isogenic GD2bright DC-ES6 with wild type
GD2dim DC-ES6 cells. Opsonization of GD2bright DC-ES6 sig-
nificantly enhanced killing by Vd2C gdT cells, which was mini-
mal in the absence of ch14.18/CHO antibody (Fig. 3B). When
Vd2C gdT cells were co-cultured overnight with GD2bright DC-
ES6, the target cells were eliminated and IFNg was produced
only when ch14.18/CHO was used as an opsonizing antibody
(Fig. 3C, representative of three donors). To determine the rela-
tionship between antigen expression and the efficiency of anti-
body-dependent killing, we calculated how much cytotoxicity
was antibody-dependent (killing with ch14.18/CHO minus kill-
ing with Rituximab control antibody) at a consistent effector:tar-
get ratio (10:1) in the panel of Ewing’s lines and in Kelly and
LAN-1 neuroblastoma lines. There was a strong correlation
between antigen expression and ADCC (r D 0.87 by Spearman
correlation, p D 0.002) but there was no correlation between
GD2 expression and antibody-independent killing (Fig. 3D).
Ch14.18/CHO alone does not directly kill Ewing’s sarcoma
even at supra-therapeutic concentrations
Published studies have demonstrated that binding of anti-
GD2 antibodies to GD2C neuroblastoma, melanoma and small
cell lung cancer cell lines leads to increased levels of cell death via
caspase-dependent and -independent pathways.15,17,22 This effect
may increase the clinical efficacy of anti-GD2 antibodies in a cell-
independent manner. We sought to determine whether this was
the case against a panel of Ewing’s cell lines; neuroblastoma cell
lines are sensitive to this direct cytotoxicity17 and were therefore
used as a positive control.
20 mg/mL of ch14.18/CHO was loaded onto a panel of
GD2-expressing or non-expressing Ewing’s sarcoma cell lines.
The level of cell death after 4 h in the absence of immune effector
cells was assessed using a 51Cr release assay and was compared to
the maximum potential 51Cr release (obtained using Triton-X
treatment) or the 51Cr release following coating with control
antibody – Rituximab (anti-CD20 mAb) at identical concentra-
tion. The amount of cell death due to ch14.18 was determined
by subtracting the spontaneous cell death in the Rituximab-
treated controls from the cell death in ch14.18/CHO treated
cells. There was detectable and reproducible direct cytotoxicity
toward GD2 positive neuroblastoma cell lines Kelly and LAN1
by ch14.18/CHO. This effect was not seen in Ewing’s sarcoma;
ch14.18/CHO had minimal cytotoxicity at the same concentra-
tion against Ewing’s sarcoma irrespective of GD2 expression; the
difference between the killing of Kelly or LAN1 and GD2bright
DC-ES6, was highly significant (p D<0.0001). Furthermore,
there was no significant difference in direct killing of the paired
GD2bright or GD2dim DC-ES6 lines by ch14.18/CHO (Fig. 4A).
To confirm that the killing of neuroblastoma cell lines was not
the result of residual complement in the heat-inactivated fetal
Figure 1. Killing of Ewing’s sarcoma cell lines in 4 h chromium release assays by (A) Vd1C gdT cells and (B) Vd1–/Vg2– gdT cells. Representative data
showing one of ﬁve donors.
www.tandfonline.com e1025194-3OncoImmunology
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calf serum used in culture medium, we repeated the experiment
after extensive washing and in the absence of serum. The presence
or absence of serum had no significant influence, indicating that
the killing of neuroblastoma was a direct effect of the antibody
rather than a complement-mediated phenomenon (Fig. 4B).
The combination of VgVd2C gdT cells, zoledronate and
ch14.18/CHO impairs growth of established neuroblastoma
and Ewing’s sarcoma in a murine model
Because of fundamental differences between murine and
human gdT cells, in vivo modeling of gdT cell function in
mice requires the use of immunodeficient animals. We evalu-
ated the effect of adoptive transfer of human zoledronate
expanded gdT cells on subcutaneous xenografts of GD2-
expressing Ewing’s sarcoma cells (TC71) in NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice which have no endogenous T or
NK cells. Our animal model of neuroblastoma used subcutane-
ous xenografts of the GD2-expressing cell line Kelly, which we
have shown to be susceptible to Vg9Vd2C gdT cell-mediated
ADCC in vitro.5 We chose TC71 as an un-manipulated GD2-
expressing model of Ewing’s sarcoma for comparison. Mice
with small established tumors were randomly assigned to treat-
ment groups, this design ensuring that therapeutic benefits of
intravenous injections of Vg9Vd2C gdT cells relies not only on
the gdT cells being able to kill the tumor cells, but also on their
ability to infiltrate the tumor from the bloodstream. Weekly
injections of zoledronate (120 mg/kg) C/– ch14.18/CHO
(300 mg per mouse) and relatively low doses of Vg9Vd2C gdT
cells (1 £ 106 cells per week) were given alongside low-dose IL-
2 (100 u/mouse i.v.) (Fig. 5A) and engraftment was evaluated
by flow cytometric analysis of blood and spleen taken at the
end of the experiment (following three cycles of treatment),
confirming successful engraftment of transferred cells in all mice
sampled (Fig. 5B). In the absence of zoledronate, gdT cells
failed to engraft, even when much higher doses (1 £ 107 cells
per dose) were used. Following three cycles of combination
treatment with zoledronate, ch14.18/CHO and Vg9Vd2C gdT
cells, tumor growth was significantly impaired when compared
to gdT cells C zoledronate only (p D 0.0015) or with ch14.18/
CHO C zoledronate (p D 0.04) (Fig. 5C, n D 4–6 per group).
Interestingly, there was a suggestion of some inhibition of
growth from the combination of ch14.18/CHO and zoledro-
nate alone in the absence of any human gdT cells though this
was not significantly different from the tumor growth rate seen
with gdT cells C zoledronate only (p D 0.19).
In the neuroblastoma model, the same pattern was
observed. In Vg9Vd2 C zoledronate treated mice, there
was exponential tumor growth; however, when ch14.18/CHO
was administered alongside the zoledronate and Vg9Vd2C
cells, there was a significant reduction in growth with tumor
shrinkage in 2/4 mice. By 20 d following the commencement
of treatment (after three cycles of treatment), the difference in
growth rate was highly significant between mice receiving
zoledronate C Vg9Vd2 and those receiving zoledronate C
Vg9Vd2 C ch14.18/CHO (p D 0.004, n D 4, Fig. 5D). As
was observed in the Ewing’s model, the addition of ch14.18/
CHO C zoledronate in the absence of Vg9Vd2C gdT cells
also led to a non-significant reduction in tumor growth com-
pared with the Vd2 C zoledronate treatment. This minor
effect of ch14.18/CHO C zoledronate was consistently
observed in repeated experiments in both the Ewing’s and neu-
roblastoma models.
Figure 2. (A) 24 h treatment with 5 mM zoledronic acid sensitizes the
Ewing’s sarcoma cell line TC71 to antibody independent lysis by Vd2C
gdT cells (n D 7, ***p D 0.001). (B) Comparative GD2 staining of Ewing’s
sarcoma and Neuroblastoma cell lines determined by ﬂow cytometry
and expressed as speciﬁc ﬂuorescence intensity (SFI). SFI is calculated by
dividing the median ﬂuorescence intensity of a sample stained with PE-
anti-GD2 with the median ﬂuorescence intensity of a sample of the
same cells stained with PE-isotype control.
e1025194-4 Volume 5 Issue 1OncoImmunology
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Discussion
We show here that the cytolytic properties of Vg9Vd2 gdT
cells are preserved in an in vivo setting, making these findings
highly translatable to early phase trials. Our new data, combined
with results that we have previously published in neuroblastoma5
indicate that maximization of this cytolytic activity has a number
of prerequisites – gdTCR engagement and engagement of
ADCC via CD16.
Many transformed cells produce increased quantities of
mavalonate pathway intermediates such as isopentenyl-5-pyro-
phosphaste (IPP) which lead to engagement of the Vg9Vd2
TCR and stimulate the gdT cells – so called “signal 1.”
gdTCR stimulation alone is insufficient to fully activate
Vg9Vd2C gdT cells; an additional co-stimulatory signal via
receptors such as NKG2D is also required.23 Transformed
cells, including Ewing’s sarcoma,24 typically express membrane
bound NKG2D ligands facilitating this costimulation and sen-
sitizing them to cytotoxic killing; however, some tumors
including neuroblastoma have been demonstrated to shed sol-
uble NKG2D ligands which can block NKG2D cross-linking
and therefore abrogate this essential second signal.9 This phe-
nomenon may in part explain the low levels of antibody-inde-
pendent killing exerted by Vg9Vd2C gdT cells against
neuroblastoma. Unlike abT cells, Vd2C gdT cells express
high levels of the low-affinity Fc Receptor FcgRIII (CD16),
the functional role of which in ADCC is most evident in NK
cells and macrophages. We previously showed that gdT
express only very low levels of the high-affinity Fcg receptors
CD32 and CD64 indicating that ADCC induced by IgG anti-
bodies occurs via CD16 ligation. CD16 provides an alternative
route for Vg9Vd2C gdT cell co-stimulation in the presence of
an appropriately opsonized target. Naturally, there is variation
in the balance of gdTCR and co-stimulatory stimulus between
tumor types and also between cell lines of similar tumor ori-
gin. This variability presents problems for the therapeutic use
of Vg9Vd2C gdT cells as it provides additional avenues of
immune escape.
Figure 3. (A) Killing of wild-type Ewing’s sarcoma cell lines by expanded Vd2C gdT cells opsonized with ch14.18/CHO anti-GD2 antibody or in the pres-
ence of a control antibody (Rituximab) (n D 3–6, **p D 0.0099). (B) Killing of isogenic GD2bright and GD2dim DC-ES6 Ewing’s cell lines by Vd2C gdT cells
in the presence of ch14.18/CHO anti-GD2 opsonizing antibody or Rituximab control antibody (n D 3, ***p D 0.0033). (C) IFNg expression of Vd2C gdT
cells in the presence of GD2bright DC-ES6. Elimination of the DC-ES6 population and production of IFNg is only seen when DC-ES6 is opsonized with
ch14.18/CHO. (D) Correlation between the GD2 stain (PE-SFI) of Ewing’s sarcoma and neuroblastoma cell lines and the degree to which Vd2C gdT cells
exert ADCC or AIC against them at effector:target ratio 10:1. R value calculated by Spearman correlation.
www.tandfonline.com e1025194-5OncoImmunology
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 L
on
do
n]
 at
 06
:59
 18
 Ja
nu
ary
 20
16
 
To overcome this variability, the stimulus to either the
gdTCR, co-stimulatory receptors or both can be artificially
enhanced. Treatment of target cells with zoledronate increases
IPP production and thereby increases the availability of
gdTCR stimulus,25 sensitizing tumor cells to Vg9Vd2C gdT
cell-mediated killing.26,27 The evidence for the clinical efficacy
of zoledronate C IL-2 combination treatment in cancer clini-
cal trials is however limited,6 suggesting that approaches for
further strengthening of the gdT cell response must be
explored.
In NK cells, CD16 engages CD3z or FceRIg homo/hetero-
dimers, which bear immunoreceptor tyrosine-based activation
motifs (ITAMs), facilitating recruitment of tyrosine kinases
ZAP70 and Syk. This triggers a signaling cascade involving SLP-
76, the p85 subunit of PI3-kinase and Grb2 leading to an
increase in intracellular Ca2C levels. The breadth of signaling
that occurs following CD16 ligation in NK cells is quite different
from the relatively small subset of molecules which are implicated
in the conventional T cell “signal 2” via co-stimulatory receptors
such as CD28. CD28 signaling is viewed as both qualitative (pro-
ducing a specific signal via a narrowly defined pathway) and
quantitative (with effect determined by signal strength).28 Our
data demonstrating the correlation of the effect (ADCC) with
GD2 staining suggests that the functional effects of CD16 liga-
tion in Vg9Vd2C gdT cells are quantitative – the strength of the
signal is directly proportional to the level of binding to the target
cell in a context where epitopes are likely to be saturated with
antibody. The level of in vitro antibody-dependent killing exerted
by gdT cells has previously been shown to correlate with the
FcgRIII (CD16) expression of the
effectors in question.5,29 Our data sup-
port the hypothesis that the number of
complete antigen-antibody-CD16
complexes is what influences the
strength of the signal.
Translational relevance
of Vg9Vd2C gdT cell ADCC
gdT cells are potent effectors of
antibody-dependent cytotoxicity that
can be expanded in a specific manner
without bystander activation of other
immune effectors.30 A number of
clinical trials have already demon-
strated that treating cancer patients
with a combination of zoledronate
and low dose IL-2 can lead to objec-
tive clinical responses in those patients
where gdT cell expansion is
achieved.6,30–32 Target opsonization
with appropriate antibody led to sig-
nificant increases in Vg9Vd2C cyto-
toxicity against tumor cells in a
number of previous in vitro stud-
ies3,5,19,29,33 but there is a paucity of
in vivo evidence supporting the com-
bination of Vg9Vd2C gdT cell activation and tumor-targeting
antibody,19,33 and this approach has never been attempted in a
clinical setting despite the availability of appropriate agents
with known safety profiles in adults and children.
Neuroblastoma is a potential model for this kind of combina-
tion treatment. GD2 expression in neuroblastoma is preserved
following treatment with anti-GD2 monoclonal antibodies,
avoiding problems of antigen loss which are often seen in other
antibody-targeted malignancies such as CD20 expressing lym-
phoma. This makes early phase trials in patients with refractory
or relapsed GD2-expressing disease a much more feasible pros-
pect. Here, we have demonstrated that, in the context of neuro-
blastoma or Ewing’s sarcoma expressing high levels of GD2,
Vg9Vd2C gdT cells can exert an antibody-dependent suppres-
sion of tumor growth, even at low doses. While the clinical utility
of targeting GD2 on neuroblastoma has already been validated, it
remains to be seen whether this will be of benefit in Ewing’s sar-
coma due to the heterogeneity of GD2 expression seen in this
disease.
The ability of Vg9Vd2C gdT cells to exert in vivo ADCC
against solid tumors is highly translatable and may have relevance
in the context of other tumor associated antigens against which
there are therapeutic antibodies. Furthermore, as there is already
extensive phase I safety data on the combination of zoledronate
C IL-2 for in vivo gdT cell expansion4,10,30-32 and also on the
combination of anti-GD2 antibodies C IL-2,11,12 combining
these two approaches would offer a route to studying the benefits
of providing an antibody alongside a specifically expanded
ADCC competent effector population.
Figure 4. (A) To determine whether the correlation between ADCC and antigen expression was due to
cellular stress imparted by the binding of antibody to GD2, we examined the killing of neuroblastoma
and Ewing’s sarcoma lines opsonized with ch14.18/CHO (20 mg/mL). High levels of spontaneous cell
death were only seen in the GD2C neuroblastoma lines, despite GD2 expression being higher in some
of the Ewing’s sarcoma lines (n D 9–42, depending on cell line, ****p D <0.0001). (B) To conﬁrm that
killing of neuroblastoma cell lines was not simply due to the binding and activation of residual comple-
ment in the serum, we compared the effects in the presence or absence of serum, and saw no signiﬁ-
cant difference (n D 5). The data is expressed as the “% of maximum killing” and represents the 51Cr
release from opsonized cells incubated in medium for 4 h as a percentage of the 51Cr release of the
same cells treated with Triton X, minus the paired result from cells treated with control antibody.
e1025194-6 Volume 5 Issue 1OncoImmunology
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Materials and Methods
Statistical analysis
Statistical analyses were performed using GraphPad Prism
Version 6.0e. Error bars, where displayed, indicate the standard
error of the mean of data from replicate independent experi-
ments. Significance of difference between samples within figures
was confirmed using paired or unpaired t-tests, depending on the
experimental setting, with p D <0.05 indicating significance.
Correlation between variables was demonstrated by Spearman
rank correlation coefficient.
Cell lines
Human neuroblastoma cells lines Kelly and LAN1 and the
human Ewing’s sarcoma cell lines A673 and Rh1 were originally
obtained from the ATCC. The Ewing’s sarcoma cell lines TC-
71 and Cado were from DSMZ (Braunschweig, Germany).
VH-64 and WE-68 cells were gifts from Frans van Valen’s labo-
ratory at the Institute of Experimental Orthopedics of Univer-
sity of Muenster, Germany. A-4573 and TC-32 were from the
cell line bank at Children’s Hospital Los Angeles. MS-PES4
and DC-ES6 were established by our group as described
previously.14
Expansion of gdT cells from PBMC
gdT cells were expanded from freshly isolated peripheral
blood mononuclear cells (PBMCs) or from isolated pure popu-
lations of gdT cells. Cells were obtained from healthy donors
following institutional review board approval. Zoledronate-
based expansions of Vg9Vd2C gdT cells were performed by
culturing freshly isolated PBMC in RPMI-1640 medium con-
taining 10% Fetal calf serum, 1% Penicillin/Streptomycin,
5 mM zoledronate (Zometa – Novartis) and 100 IU/mL IL-2
(PeproTech 200–02), which was refreshed three times weekly.
After 14 d of expansion, gdT cell isolation was performed using
the Miltenyi gdT cell isolation kit (130-092-892) in accordance
with the manufacturer’s protocol. Expansion of Vd1C or
Vd1–/Vd2– gdT cells were performed as previously described.5
Cells were incubated at 37C, 5% CO2.
Figure 5. (A) Treatment schedule of mice used in in vivo experiments (B) Engraftment of Vg9Vd2C gdT cells in NSG mice bearing TC71 Ewing’s sarcoma
(representative of six mice sampled) or Kelly neuroblastoma (representative of eight mice sampled) xenografts. Samples taken after culling, following
three serial intravenous injections of 1 £ 106 gdT cells. (C) Fold change in tumor size of TC71 xenografts in NSG mice receiving Vg9Vd2 C zoledronate,
Vg9Vd2 C zoledronate C ch14.18/CHO or zoledronate C ch14.18/CHO (D) – fold change in tumor size of Kelly xenografts in NSG mice receiving Vg9Vd2
C zoledronate, Vg9Vd2 C zoledronateC ch14.18/CHO or zoledronateC ch14.18/CHO.
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Generation of GD2C DC-ES6
Wild-type DC-ES6 were transduced with SFG gammaretrovi-
rus encoding GD2 and GD3 synthase co-expressed via foot and
mouth virus 2A self-cleaving peptide sequence, kindly provided
by M Pule (UCL). After transduction, single GD2-expressing
clones were generated by limiting dilution, and expanded.
Antibodies
The following antibodies were used in this investigation:
Treatment grade antibodies Ch14.18/CHO and rituximab were
provided by Great Ormond Street Hospital pharmacy. Mouse
anti-human CD3-PE/Cy7 (Biolegend 3000316; clone HIT3a),
mouse anti-human TCR Vd1-FITC (Thermo Scientific
TCR2730; clone TS8.2), mouse anti-human TCR Vd2-PE
(BioLegend 331408; clone B6), mouse anti-human CD45-APC
(Biolegend 304012; clone HI30), mouse anti-human CD45-
APC (Biolegend 304006; clone HI30), rat anti-human/mouse
CD11b (Biolegend 101228; clone M1/70), mouse anti-human
IFNg-APCCy7 (Biolegend 502530; clone 4S.B3). Live/dead
staining was performed using ZombieTM Yellow fixable viability
kit (Biolegend 423104), mouse anti-ganglioside GD2-PE (Biole-
gend 357304, clone 14G2a). Compensation was carried out
using single-color controls and eBioScience OneComp eBeads
(eBioScience 01-1111). When experiments regarding compara-
tive GD2 expression of neuroblastoma and Ewing’s sarcoma cell
lines were being carried out, 0.5 £ 106 cells were resuspended in
100 mL of buffer and labeled with 3mL of antibody (final con-
centration 1.5 mg/mL) for 10 min in the fridge before washing
twice in PBS. Flow cytometry analysis was carried out on BD
LSRII or BD FACSAria flow cytometers and results were ana-
lyzed using FlowJo vX.0.7.
Cytotoxicity assays
Expanded and purified gdT cells were used as effector cells.
Target cells were coated either with opsonizing antibody or a
non-targeting isotype control and labeled with 100 mCi
Na2
51CrO4 in cell culture and tested in a standard chromium
release assay as previously described. A range of E:T ratios was
used in each case (10:1, 5:1, 2.5:1, 1.25:1) and cells were incu-
bated for 4 h for each assay. Anti-GD2 antibody ch14.18/CHO
(clinical grade) was used as a GD2-specific opsonizing antibody,
with rituximab anti-CD20 (clinical grade) as a control.
The direct cytotoxicity of ch14.18/CHO was determined by
the following formula (background 51Cr release from ch14.18/
CHO opsonized/Triton-X induced 51Cr release from ch14.18/
CHO opsonized) – (background 51Cr release from Rituximab
treated cells/Triton-X-induced 51Cr release from Rituximab-
treated cells).
Animal experiments
All experiments and procedures involving animals were con-
ducted in accordance with the relevant laws and institutional pro-
cedures, approved by the UK government. Mice were housed in
pathogen-free conditions in individually ventilated cages. Ani-
mals were originally obtained from Charles River Laboratories
(Wilmington, MA) and a breeding colony was subsequently gen-
erated and maintained locally.
Adult female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice
were injected with 1.5 £ 106 tumor cells (TC-71 or Kelly) sub-
cutaneously, and tumor growth was monitored using electronic
callipers. Once the tumors reached approximately 3 mm in
diameter, mice were randomized to treatment groups and groups
were coded in a way that had no relation to the treatment
received, to aid blinding. Weekly intraperitoneal injections of
zoledronate (120 mg/kg) C/- ch14.18/CHO (300 mg per
mouse) were administered. In mice who were assigned to the
groups receiving gdT cells, 1 £ 106 purified Vd2C cells were
injected intravenously on the day after injection of the zoledrona-
teCch14.18/CHO. 100 u of human IL-2 were injected intrave-
nously alongside the gdT cells. Fold change in tumor size was
calculated based on the size at Day 0 of treatment. Mice were
culled when the average tumor diameter reached 15 mm. Blood
and spleen samples were taken after culling. Blood samples were
treated with ACK lysis buffer (Life Technologies A10492-01)
before staining for FACS analysis. Spleen samples were passed
through a 70 mM cell strainer before being treated with ACK
lysis buffer and being stained for FACS analysis to confirm
Vd2C gdT cell engraftment.
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